10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers)

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers)

Asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness, tissue remodeling, mucosal edema, mucus hypersecretion, and variable, reversible airflow limitation. In Canada, asthma affects over 3.8 million children and adults, representing one of the most frequent respiratory conditions encountered in community and hospital pharmacy practice. The Canadian Thoracic Society (CTS) Asthma Clinical Practice Guidelines provide an evidence-based clinical framework emphasizing that asthma is fundamentally an inflammatory disease; effective management requires addressing underlying chronic airway inflammation rather than relying solely on acute bronchodilation.

---

Objective Diagnostic Criteria for Asthma

Clinical suspicion of asthma is raised by episodic respiratory symptoms—including wheezing, shortness of breath, chest tightness, and cough—that vary over time and in intensity, frequently worsening at night or in the early morning and triggered by viral respiratory tract infections, cold dry air, exercise, chemical irritants, or aeroallergens. However, physical examination and clinical history alone are insufficient for confirmation. The CTS mandates objective demonstration of variable, reversible airflow obstruction.

1. Spirometry with Bronchodilator Reversibility (First-Line Confirmation)

Spirometry is the definitive diagnostic modality for individuals aged 6 years and older. Baseline airflow limitation is defined by a reduced forced expiratory volume in 1 second to forced vital capacity ratio ($FEV_1/FVC$):

• Adults: $FEV_1/FVC$ below the lower limit of normal (LLN) from age-adjusted reference equations, roughly less than $0.75$ to $0.80$. The fixed $0.70$ cut-off is the COPD convention, not the CTS asthma criterion.
• Children (6–17 years): $FEV_1/FVC$ below the LLN, roughly less than $0.80$ to $0.90$.

                          CTS OBJECTIVE ASTHMA DIAGNOSTIC WORKFLOW
                          
                        Patient with Recurrent Wheeze, Cough, Dyspnea
                                              │
                                              ▼
                                Baseline Spirometry (Pre-BD)
                                              │
                     ┌────────────────────────┴────────────────────────┐
                     ▼                                                 ▼
             FEV1/FVC Reduced                                  FEV1/FVC Normal
                     │                                                 │
                     ▼                                                 ▼
        Administer 200-400 mcg Salbutamol                 Alternate Objective Assessment
        Wait 15 minutes and repeat FEV1                        (Choose one of below)
                     │                                                 │
      ┌──────────────┴──────────────┐                 ┌────────────────┼────────────────┐
      ▼                             ▼                 ▼                ▼                ▼
 FEV1 increases               FEV1 increases      Methacholine     Peak Expiratory   Exercise Challenge
 ≥ 12% AND ≥ 200 mL          < 12% or < 200 mL   Challenge Test   Flow Variability    Fall in FEV1
      │                             │             PC20 ≤ 4 mg/mL   Diurnal Var > 15%   ≥ 10% to 15%
      ▼                             ▼                 │                │                │
 DIAGNOSIS CONFIRMED           Further testing ───────┴────────────────┴────────────────┘
                               (Methacholine/PEF)

2. Alternative Objective Diagnostic Modalities

When baseline spirometry is normal or bronchodilator reversibility is equivocal, alternative tests are utilized:

• Bronchial Provocation (Methacholine Challenge Test): The patient inhales escalating concentrations of methacholine, a muscarinic agonist that induces bronchoconstriction in hyperresponsive airways. A provocative concentration causing a 20% decline in $FEV_1$ ($PC_{20}$) of ≤ 4.0 mg/mL is highly sensitive and diagnostic for airway hyperresponsiveness; a $PC_{20}$ between 4.1 and 16 mg/mL is considered borderline; a $PC_{20} > 16$ mg/mL effectively excludes active asthma.
• Peak Expiratory Flow (PEF) Diurnal Variability: The patient records morning and evening PEF before bronchodilator use over 1 to 2 weeks. Diurnal variability calculated as $\frac{\text{PEF}_{\text{max}} - \text{PEF}_{\text{min}}}{\text{PEF}_{\text{mean}}} \times 100\%$ that exceeds 15% to 20% confirms variable airflow limitation.
• Exercise Challenge: A fall in $FEV_1$ of ≥ 10% to 15% after standardized treadmill or bicycle ergometer exercise supports exercise-induced bronchoconstriction.
• Therapeutic Trial of Anti-Inflammatory Therapy: An improvement in $FEV_1$ of ≥ 12% and ≥ 200 mL (or PEF by > 20%) after 4 to 6 weeks of daily inhaled corticosteroid (ICS) therapy confirms reversible obstruction.

---

Canadian Thoracic Society (CTS) Criteria for Asthma Control

The fundamental goal of asthma management is to achieve and maintain disease control, minimizing both current impairment (daytime/nighttime symptoms, activity limitation, reliever use) and future risk (exacerbations, accelerated lung function decline, medication adverse effects). The CTS defines asthma control using seven rigorous clinical parameters assessed over the preceding 4 weeks:

---

CTS 2021 Pharmacotherapy: Matching Treatment to Asthma Severity

Historically, asthma management relied on short-acting beta2-agonists (SABA: salbutamol) for symptom relief. Trials such as SYGMA and PRACTICAL, and large observational datasets, show that relying on SABA without an inhaled corticosteroid (ICS) leaves inflammation untreated and raises the risk of severe exacerbations and asthma death. Dispensing more than 2 SABA inhalers per year is a CTS marker of higher exacerbation risk, and very high yearly use (around 12 canisters) is associated with asthma mortality.

Children under 12 follow the same principle: daily ICS + PRN SABA is preferred for mild asthma. PRN budesonide-formoterol is not an option under 12.

Using Budesonide-Formoterol as a Reliever

• Rationale: formoterol starts working within about 1 to 3 minutes, like salbutamol. Each relief inhalation therefore also delivers a dose of corticosteroid, so the anti-inflammatory dose rises when symptoms rise.
• As-needed use (mild asthma, ≥ 12 years): budesonide-formoterol 200/6 mcg, 1 inhalation as needed. The Canadian product limits are up to 6 inhalations on any single occasion and 8 inhalations per day (up to 12 for a short time under medical advice).
• Maintenance-and-reliever therapy (moderate to severe): the same inhaler is used for daily maintenance (for example, 1 to 2 inhalations once or twice daily) and as the reliever. A patient using it this way should not also be given salbutamol for routine relief.

Daily ICS with SABA Reliever

• A SABA (salbutamol 100 mcg, 1 to 2 puffs PRN) remains an acceptable reliever only alongside daily ICS-containing maintenance therapy in patients with more than very mild asthma.
• Before any step-up, check adherence, inhaler technique, triggers, and comorbidities (rhinitis, GERD, obesity, smoking). These explain most apparent treatment failures.

---

Stepwise Pharmacotherapy & Controller Drug Classes

                            CTS STEPWISE CONTROLLER ESCALATION (≥ 12 YEARS)

  [Very mild]  PRN SABA (low risk)  |  daily low-dose ICS or PRN bud/form (higher risk)
     │
  [Mild]       Daily low-dose ICS + PRN SABA  (PRN bud/form if daily ICS adherence stays poor)
     │
  [Moderate]   Low-dose ICS/LABA + PRN SABA  OR  bud/form maintenance-and-reliever
     │         (Alternatives: medium-dose ICS, or low-dose ICS + LTRA)
     │
  [Severe]     Medium-to-high dose ICS/LABA +/- add-on LAMA (tiotropium Respimat)
     │
  [Refractory] Specialist care: biologic monoclonal antibody by phenotype

1. Inhaled Corticosteroids (ICS) — Foundational Anti-Inflammatory Therapy

Inhaled corticosteroids represent the cornerstone of chronic asthma pharmacotherapy. By binding to cytosolic glucocorticoid receptors, they translocate to the nucleus to transrepress transcription factors (NF-κB, AP-1), potently suppressing the transcription of pro-inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes (COX-2, iNOS), while restoring beta2-receptor sensitivity.

2. Long-Acting Beta2-Agonists (LABA)

• Agents: Formoterol (rapid onset [1–3 min], duration 12 h, full/high intrinsic efficacy), Salmeterol (slower onset [15–30 min], duration 12 h, partial agonist).
• Black Box Warning & Clinical Rule: LABAs must NEVER be used as monotherapy in asthma. In the SMART trial and large safety registries, LABA monotherapy without concurrent ICS masked underlying airway inflammation, predisposing patients to fatal bronchospastic episodes. LABAs must always be co-prescribed with an ICS, ideally in a fixed-dose combination inhaler (e.g., budesonide-formoterol [Symbicort], fluticasone-salmeterol [Advair], fluticasone furoate-vilanterol [Breo Ellipta], mometasone-formoterol [Zenhale]).

3. Long-Acting Muscarinic Antagonists (LAMA)

• Agent: Tiotropium bromide (Spiriva Respimat 1.25 mcg/actuation; 2 inhalations once daily = 2.5 mcg daily, or 5 mcg daily).
• Role: Indicated as an add-on bronchodilator in Step 4 or 5 for patients with persistent airflow obstruction or recurrent exacerbations despite adherence to medium-to-high dose ICS-LABA. It competitively blocks muscarinic M3 receptors on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction and reducing mucus hypersecretion.

4. Leukotriene Receptor Antagonists (LTRA)

• Agent: Montelukast (Singulair 10 mg PO once daily in adults; 5 mg daily in children 6–14 years; 4 mg daily in children 2–5 years; taken in the evening).
• Mechanism: High-affinity competitive antagonist of the cysteinyl leukotriene 1 ($CysLT_1$) receptor, blocking the actions of $LTC_4$, $LTD_4$, and $LTE_4$. Prevents leukotriene-induced bronchoconstriction, vascular permeability, and mucosal edema.
• Clinical Indications: Effective as an add-on therapy in patients with concomitant allergic rhinitis, aspirin-exacerbated respiratory disease (AERD / Samter's triad: asthma, chronic rhinosinusitis with nasal polyps, and severe bronchospasm upon ingestion of aspirin or COX-1 inhibitors), or exercise-induced bronchoconstriction (EIB).

5. Biologic Therapies for Severe Refractory Asthma (Step 5)

For patients with severe asthma whose disease remains uncontrolled despite maximal optimized inhaler therapy (high-dose ICS-LABA + LAMA), phenotypic biomarker assessment (blood eosinophil count, total serum IgE, fractional exhaled nitric oxide [FeNO], aeroallergen sensitization) directs targeted monoclonal antibody therapy:

---

Acute Asthma Exacerbations: Severity Triage & Emergency Pharmacotherapy

An acute asthma exacerbation is an acute or subacute worsening in symptoms and lung function compared to the patient's baseline, representing a potentially fatal medical emergency. Resuscitation requires immediate objective triage and aggressive pharmacological stabilization.

Clinical Severity Stratification

• Mild-to-Moderate Exacerbation: Talks in phrases, prefers sitting to lying, respiratory rate increased, heart rate 100–120 bpm, $SaO_2$ (on room air) 90%–95%, $PEF > 50\%$ of personal best or predicted.
• Severe / Life-Threatening Exacerbation: Talks in single words, hunched forward, agitated or drowsy, respiratory rate > 30 breaths/min, accessory muscle use, suprasternal indrawing, heart rate > 120 bpm (or bradycardia in terminal fatigue), $SaO_2 < 90\%$, "silent chest" on auscultation (absence of wheezing indicating critical inability to move air), $PEF \le 50\%$ of personal best.

                         ACUTE ASTHMA EXACERBATION RESUSCITATION ALGORITHM
                         
                        Severe Exacerbation: Dyspneic, Accessory Muscle Use, PEF ≤ 50%
                                              │
                                              ▼
                                  IMMEDIATE TRIAGE BUNDLE
                                              │
      ┌───────────────────────┬───────────────┴───────────────┬───────────────────────┐
      ▼                       ▼                               ▼                       ▼
HIGH-DOSE SABA          INHALED ANTICHOLINERGIC         SYSTEMIC STEROID         CONTROLLED OXYGEN
• Salbutamol 4-8 puffs  • Ipratropium bromide           • Oral Prednisone        • Titrate via nasal
  pMDI + spacer q20m      4-8 puffs pMDI + spacer         50 mg PO stat            prongs to target
  x 3 doses, OR           q20m x 3 doses (with SABA)    • Equal efficacy to IV     SaO2 93% - 95%
• 2.5-5 mg nebulized    • 500 mcg nebulized             • 5-day course           • Avoid hyperoxia
                                                          (no taper needed)        in COPD overlap
                                              │
                               Re-evaluate Clinical Status at 60 min
                                              │
                     ┌────────────────────────┴────────────────────────┐
                     ▼                                                 ▼
         Good Response (PEF > 70%)                         Poor Response / Impending Arrest
         • Discharge on 5-day Prednisone                   • IV Magnesium Sulfate 2 g over 20 min
         • Step up baseline controller                     • ICU transfer / mechanical ventilation

Pharmacotherapeutic Protocols in Acute Exacerbations

1. Repetitive Inhaled Short-Acting Beta2-Agonists (SABA):
   • Salbutamol: Administer 4 to 8 puffs via pMDI with a valved holding chamber every 20 minutes for 3 doses (first hour), then every 1 to 4 hours as needed. Alternatively, administer 2.5 to 5.0 mg via wet nebulization driven by compressed air (or oxygen). Delivering salbutamol via pMDI with a spacer is clinically equivalent or superior in lung deposition to wet nebulization while causing less tachycardia.
2. Inhaled Anticholinergics (Ipratropium Bromide):
   • Dosing: 4 to 8 puffs via pMDI with spacer (or 500 mcg nebulized) combined with salbutamol every 20 minutes for 3 doses in moderate-to-severe exacerbations.
   • Rationale: Blocks vagally mediated bronchoconstriction. Clinical trials demonstrate that adding ipratropium to salbutamol produces greater bronchodilation, faster improvement in $FEV_1$, and a statistically significant reduction in hospital admissions (NNT ≈ 12) compared to salbutamol alone.
3. Early Systemic Corticosteroids:
   • Agent & Dose: Prednisone 50 mg orally once daily for 5 days (pediatric dose: 1 mg/kg/day up to a maximum of 50 mg daily for 3 to 5 days). In hospitalized patients unable to swallow, intravenous methylprednisolone (40–80 mg/day in divided doses) is utilized.
   • Onset & Rationale: Anti-inflammatory effects require 4 to 6 hours to manifest clinically; early administration in the emergency department reduces hospital admission rates and prevents relapse.
   • Tapering Rule: A 5-day short course of oral prednisone requires no gradual dosage taper; the hypothalamic-pituitary-adrenal (HPA) axis is not suppressed by courses lasting ≤ 14 days, and abrupt discontinuation does not trigger rebound exacerbations.
4. Oxygen Therapy:
   • Administer controlled supplementary oxygen via nasal cannula or simple face mask titrated to maintain an $SaO_2$ of 93% to 95% (94%–98% in pregnant patients or children). Hyperoxia ($SaO_2 > 98\%$) should be avoided, as it causes reflex vasoconstriction and worsening ventilation-perfusion mismatch.
5. Intravenous Magnesium Sulfate:
   • Dose: 2.0 grams IV infused over 20 minutes in adults with severe exacerbations ($FEV_1 < 50\%$ predicted) that fail to respond to initial inhaled bronchodilators and systemic steroids. Magnesium acts as a physiological calcium antagonist, blocking calcium influx into bronchial smooth muscle cells and triggering potent smooth muscle relaxation.

---

Clinical Case Vignette: Assessing Control & Regimen Escalation

A 28-year-old female teacher with a 6-year history of asthma presents to your community pharmacy requesting a refill of her salbutamol pMDI. Pharmacy dispensing records reveal she has picked up 4 canisters of salbutamol over the past 5 months. She takes fluticasone propionate 125 mcg pMDI 1 puff BID.

Clinical Assessment:

• Patient Interview: She wakes up coughing approximately 2 nights per week. She uses her salbutamol inhaler 4 to 5 days per week (1–2 puffs each time) when climbing stairs at school or during cold weather. She missed 2 days of work last month due to "chest tightness and wheezing."
• Inhaler Technique: Demonstrates good pMDI technique without a spacer, but admits she frequently rushes and does not rinse her mouth afterward.
• Control Evaluation (CTS Criteria):
  • Daytime symptoms: 4–5 days/week (uncontrolled; target ≤ 2 days/week)
  • Nighttime awakenings: 2 nights/week (uncontrolled; target < 1 night/week)
  • Reliever frequency: 4–5 times/week (uncontrolled; target ≤ 2 doses/week)
  • Work absenteeism: 2 days missed (uncontrolled; target 0 days missed)
  • Over-reliance on SABA: 4 canisters in 5 months (~10 canisters/year; dangerously elevated exacerbation risk).

Pharmacotherapeutic Care Plan:

1. Identify the Safety Gap: The patient has markedly uncontrolled asthma with excessive SABA reliance and inadequate anti-inflammatory coverage.
2. Therapeutic Escalation Options:
   • Option A (CTS moderate asthma): Switch to budesonide-formoterol 200/6 mcg Turbuhaler as maintenance-and-reliever therapy: 1 inhalation BID plus 1 inhalation PRN for symptom relief. Every reliever dose then also delivers corticosteroid, and standalone salbutamol is stopped.
   • Option B (CTS moderate asthma): Step up to a low-dose ICS/LABA combination (e.g., fluticasone-salmeterol 100/50 mcg Diskus 1 inhalation BID), keeping salbutamol PRN for relief only.
   • Either way, first correct technique and adherence, and recheck control in 2 to 3 months.
3. Counseling & Prevention: Introduce a valved holding chamber for pMDI use (if continuing pMDI), reinforce mouth rinsing after every ICS dose, and provide an updated, written Asthma Action Plan detailing green, yellow (symptom escalation: double ICS or increase SMART inhalations), and red zones (urgent care).